Prevention of Growth Failure in Turner Syndrome: Long-Term Results of Early Growth Hormone Treatment in the "Toddler Turner" Cohort.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

However, whether the early catch-up growth would result in greater near-adult height (NAH) was unknown.

Therefore, this extension study examined the long-term effects of toddler-age GH treatment on height, pubertal development, and safety parameters.

Who Took Part

By PubMed's age tags, the people studied were infants, young children and teenagers, women only.

Toddler Turner study participants were invited to enroll in a 10-year observational extension study for annual assessments of growth, pubertal status, and safety during long-term GH treatment to NAH for both ET and EUT groups.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

The subject headings attached to it are Body Height, Growth Disorders, Human Growth Hormone, Puberty and Turner Syndrome.

The authors tagged it with the keywords Childhood, Final height, Near-adult height, Prepuberty, Safety and Thelarche.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.